Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2017

Publisher Name :
Date: 10-Nov-2017
No. of pages: 153
Inquire Before Buying

In the last several years, global market of drugs for herpes labialis (oral herpes) developed smoothly, with an average growth rate of 4.9%. In 2016, global consumption value of drugs for herpes labialis (oral herpes) is nearly 2000 M USD.

This report studies Drugs for Herpes Labialis (Oral Herpes) in Global market, especially in North America, Europe, China, Rest of Asia, focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering

GSK

Novartis

Teva

Mylan

Cadila

Apotex

Daewoong Pharmaceutical

Livzon

Luoxin

Med shine

Bayer (Campho Phenique)

Blistex

Kelun Group

Hikma

Haiwang

Carmex

Cipher

Market Segment by Regions, this report splits Global into several key Regions, with revenue, market share and growth rate of Drugs for Herpes Labialis (Oral Herpes) in these regions, from 2012 to 2022 (forecast), like

North America

Europe

China

Rest of Asia

Latin America

Middle East and Africa

Split by Product Types, with revenue market share and growth rate of each type, can be divided into

Aciclovir

Valacyclovir

Famciclovir

Docosanol

Other

Split by applications, this report focuses on revenue market share and growth rate of Drugs for Herpes Labialis (Oral Herpes) in each application, can be divided into

External Use

Oral

Injection

Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2017

Table of Contents
1 Drugs for Herpes Labialis (Oral Herpes) Market Overview 1
1.1 Product Overview and Scope of Drugs for Herpes Labialis (Oral Herpes) 1
1.1.1 Definition of Drugs for Herpes Labialis (Oral Herpes) 1
1.1.2 Specifications of Drugs for Herpes Labialis (Oral Herpes) 2
1.2 Drugs for Herpes Labialis (Oral Herpes) Segment by Types and Drugs Types 3
1.2.1 Global Revenue Market Share of Drugs for Herpes Labialis (Oral Herpes) by Types 3
1.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales and Growth (%) Comparison by Drug Type (2012-2022) 7
1.3 Drugs for Herpes Labialis (Oral Herpes) Segment by Applications 8
1.3.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Comparison by Applications (2012-2022) 8
1.3.2 External Use 9
1.3.3 Oral 9
1.3.4 Injection 9
1.4 Drugs for Herpes Labialis (Oral Herpes) Market by Regions 10
1.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size and Growth (%) Comparison by Regions 10
1.4.2 North America Status and Prospect (2012-2022) 11
1.4.3 China Status and Prospect (2012-2022) 12
1.4.4 Europe Status and Prospect (2012-2022) 13
1.4.5 Rest of Asia Status and Prospect (2012-2022) 14
1.4.6 Latin America Status and Prospect (2012-2022) 15
1.4.7 Middle East and Africa Status and Prospect (2012-2022) 16
1.5 Global Market Size (Value) of Drugs for Herpes Labialis (Oral Herpes) (2012-2022) 17
2 Global Drugs for Herpes Labialis (Oral Herpes) Market Competition by Manufacturers 18
2.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Share by Manufacturers (2016 and 2017) 18
2.2 Global Drugs for Herpes Labialis (Oral Herpes) Gross and Share by Manufacturers (2016 and 2017) 21
2.3 Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin of Manufacturers (2016 and 2017) 24
2.4 Manufacturers Drugs for Herpes Labialis (Oral Herpes) Headquarters, Sales Area 26
2.5 Drugs for Herpes Labialis (Oral Herpes) Market Competitive Situation and Trends 28
2.5.1 Drugs for Herpes Labialis (Oral Herpes) Market Concentration Rate 28
2.5.2 Drugs for Herpes Labialis (Oral Herpes) Market Share of Top 3 and Top 5 Manufacturers 29
2.5.3 Mergers & Acquisitions, Expansion 30
3 Global Drugs for Herpes Labialis (Oral Herpes) Revenue (Value) by Regions (2012-2017) 31
3.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue (Value) and Market Share by Regions (2012-2017) 31
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Gross and Market Share by Regions (2012-2017) 33
3.3 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 35
3.4 North America Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
3.5 Europe Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
3.6 China Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
3.7 Rest of Asia Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
3.8 Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
3.9 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
4 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin Trend by Type 39
4.1 By Product Catalog 39
4.1.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Product Catalog (2012-2017) 39
4.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Gross and Market Share (%) by Product Catalog (2012-2017) 41
4.1.3 Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin by Type (2012-2017) 43
4.2 By Drug Type 43
4.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Drug Type (2012-2017) 43
4.2.2 Global Drugs for Herpes Labialis (Oral Herpes) Gross and Market Share (%) by Drug Type (2012-2017) 45
4.2.3 Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin by Type (2012-2017) 47
5 Global Drugs for Herpes Labialis (Oral Herpes) Market Analysis by Applications 48
5.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Market Share by Applications (2012-2017) 48
5.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Growth Rate (%) by Applications (2012-2017) 50
6 Analysis of Drugs for Herpes Labialis (Oral Herpes) Industry Key Manufacturers 51
6.1 GSK 51
6.1.1 Company Profile 51
6.1.2 Product Information 52
6.1.3 Revenue, Cost, Gross, and Gross Margin 53
6.2 Novartis 54
6.2.1 Company Profile 54
6.2.2 Product Information 55
6.2.3 Revenue, Cost, Gross, and Gross Margin 55
6.3 Teva 56
6.3.1 Company Profile 56
6.3.2 Product Information 57
6.3.3 Revenue, Cost, Gross, and Gross Margin 59
6.4 Mylan 59
6.4.1 Company Profile 59
6.4.2 Product Information 60
6.4.3 Revenue, Cost, Gross, and Gross Margin 62
6.5 Cadila 62
6.5.1 Company Profile 62
6.5.2 Product Information 63
6.5.3 Revenue, Cost, Gross, and Gross Margin 64
6.6 Apotex 64
6.6.1 Company Profile 64
6.6.2 Product Information 65
6.6.3 Revenue, Cost, Gross, and Gross Margin 66
6.7 Daewoong 66
6.7.1 Company Profile 66
6.7.2 Product Information 67
6.7.3 Revenue, Cost, Gross, and Gross Margin 68
6.8 Livzon 68
6.8.1 Company Profile 68
6.8.2 Product Information 69
6.8.3 Revenue, Cost, Gross, and Gross Margin 70
6.9 Luoxin 70
6.9.1 Company Profile 70
6.9.2 Product Information 72
6.9.3 Revenue, Cost, Gross, and Gross Margin 72
6.10 Med shine 73
6.10.1 Company Profile 73
6.10.2 Product Information 74
6.10.3 Revenue, Cost, Gross, and Gross Margin 74
6.11 Bayer (Campho Phenique) 75
6.11.1 Company Profile 75
6.11.2 Product Information 76
6.11.3 Revenue, Cost, Gross, and Gross Margin 76
6.12 Blistex 77
6.12.1 Company Profile 77
6.12.2 Product Information 78
6.12.3 Revenue, Cost, Gross, and Gross Margin 78
6.13 Kelun Group 79
6.13.1 Company Profile 79
6.13.2 Product Information 80
6.13.3 Revenue, Cost, Gross, and Gross Margin 80
6.14 Hikma 81
6.14.1 Company Profile 81
6.14.2 Product Information 82
6.14.3 Revenue, Cost, Gross, and Gross Margin 82
6.15 Haiwang 82
6.15.1 Company Profile 82
6.15.2 Product Information 83
6.15.3 Revenue, Cost, Gross, and Gross Margin 84
6.16 Carmex 84
6.16.1 Company Profile 84
6.16.2 Product Information 85
6.16.3 Revenue, Cost, Gross, and Gross Margin 85
6.17 Cipher 86
6.17.1 Company Profile 86
6.17.2 Product Information 87
6.17.3 Revenue, Cost, Gross, and Gross Margin 87
7 Drugs for Herpes Labialis (Oral Herpes) Manufacturing Cost Analysis 88
7.1 Drugs for Herpes Labialis (Oral Herpes) Key Raw Materials and Manufacturing Equipment Analysis 88
7.1.1 Drugs for Herpes Labialis (Oral Herpes) Key Raw Materials Analysis 88
7.1.2 Raw Materials Sources of Drugs for Herpes Labialis (Oral Herpes) Major Manufacturers 89
7.1.3 Drugs for Herpes Labialis (Oral Herpes) Key Manufacturing Equipment Analysis 90
7.2 Proportion of Manufacturing Cost Structure 91
7.2.1 Raw Materials 92
7.2.2 Labor Cost 92
7.2.3 Manufacturing Expenses 97
7.2.4 Other Costs Analysis 97
7.3 Manufacturing Process Analysis of Drugs for Herpes Labialis (Oral Herpes) 103
8 Industrial Chain, Sourcing Strategy and Downstream Buyers 104
8.1 Drugs for Herpes Labialis (Oral Herpes) Industrial Chain Analysis 104
8.2 Upstream Raw Materials Sourcing 104
8.3 Downstream Buyers 105
9 Marketing Strategy Analysis, Distributors/Traders 108
9.1 Marketing Channel 108
9.1.1 Direct Marketing 108
9.1.2 Indirect Marketing 109
9.1.3 Marketing Channel Development Trend 109
9.2 Market Positioning 109
9.2.1 Pricing Strategy 109
9.2.2 Brand Strategy 110
9.2.3 Target Client 110
9.3 Distributors/Traders List 110
10 Market Effect Factors Analysis 111
10.1 Market Drivers 111
10.2 Consumer Needs/Customer Preference Change 111
10.3 Economic/Political Environmental Change 111
11 Global Drugs for Herpes Labialis (Oral Herpes) Market Forecast (2017-2022) 120
11.1 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 120
11.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast by Regions (2017-2022) 120
11.2.1 North America Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 122
11.2.2 Europe Drugs for Herpes Labialis (Oral Herpes) and Revenue Forecast (2017-2022) 123
11.2.3 Rest of Asia Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 124
11.2.4 Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 125
11.2.5 Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 126
11.2.6 China Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast (2017-2022) 127
11.3 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast by Type (2017-2022) 127
11.3.1 by Product Catalog 127
11.3.2 by Drug Type 128
11.4 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast by Application (2017-2022) 130
12 Research Findings and Conclusion 131
13 Methodology and Data Source 132
13.1 Methodology/Research Approach 132
13.1.1 Research Programs/Design 132
13.1.2 Market Size Estimation 133
13.1.3 Market Breakdown and Data Triangulation 134
13.2 Data Source 135
13.2.1 Secondary Sources 135
13.2.2 Primary Sources 136
13.3 Disclaimer 137
13.4 Author List 138
List of Tables and Figures
Figure Picture of Drugs for Herpes Labialis (Oral Herpes) 1
Table Specifications of Drugs for Herpes Labialis (Oral Herpes) 2
Table Classification of Drugs for Herpes Labialis (Oral Herpes) 3
Figure Global Revenue Market Share of Drugs for Herpes Labialis (Oral Herpes) by Types in 2016 4
Figure Product Picture of Valacyclovir 4
Figure Product Picture of Aciclovir 5
Figure Product Picture of Famciclovir 6
Figure Docosanol Picture 6
Table Classification Comparison of Different Types of Drugs for Herpes Labialis (Oral Herpes) 7
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) by Drug Type in 2016 7
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Comparison by Applications (2012-2022) 8
Figure Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Applications in 2016 8
Figure External Use Examples 9
Figure Oral Examples 9
Figure Injection Examples 10
Table Global Market Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Comparison by Regions 2012-2022 10
Figure North America Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 11
Figure China Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 12
Figure Europe Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 13
Figure Rest of Asia Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 14
Figure Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 15
Figure Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 16
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate (2012-2022) 17
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) by Manufacturers (2016 and 2017) 18
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Manufacturers (2016 and 2017) 19
Figure 2016 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Manufacturers 20
Figure 2017 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share by Manufacturers 21
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross (M USD) of Key Manufacturers (2016 and 2017) 21
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Share by Manufacturers (2016 and 2017) 22
Figure 2016 Drugs for Herpes Labialis (Oral Herpes) Gross Share by Manufacturers 23
Figure 2017 Drugs for Herpes Labialis (Oral Herpes) Gross Share by Manufacturers 24
Table Global Market Drugs for Herpes Labialis (Oral Herpes) Gross Margin of Key Manufacturers (2016 and 2017) 24
Figure Global Market Drugs for Herpes Labialis (Oral Herpes) Gross Margin of Key Manufacturers in 2016 25
Figure Global Market Drugs for Herpes Labialis (Oral Herpes) Gross Margin of Key Manufacturers in 2017 26
Table Manufacturers Drugs for Herpes Labialis (Oral Herpes) Headquarters and Sales Area 26
Figure Drugs for Herpes Labialis (Oral Herpes) Revenue Market Concentration Rate in 2016 28
Figure Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share of Top 3 Manufacturers in 2016 29
Figure Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share of Top 5 Manufacturers in 2016 29
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) by Regions (2012-2017) 31
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Regions (2012-2017) 31
Figure 2012-2017 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Regions 32
Table 2016 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Regions 33
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross (M USD) by Regions (2012-2017) 33
Figure Global Drugs for Herpes Labialis (Oral Herpes) Gross and Market Share by Regions (2012-2017) 34
Figure 2012-2017 Global Drugs for Herpes Labialis (Oral Herpes) Gross Market Share by Regions 34
Table 2016 Global Drugs for Herpes Labialis (Oral Herpes) Gross Market Share by Regions 35
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 35
Table North America Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
Table Europe Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
Table China Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 36
Table Rest of Asia Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
Table Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
Table Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin (2012-2017) 37
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) by Product Catalog (2012-2017) 39
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share (%) by Product Catalog (2012-2017) 39
Figure Revenue Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Product Catalog (2012-2017) 40
Figure 2016 Revenue Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Product Catalog 40
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross (M USD) by Product Catalog (2012-2017) 41
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Share (%) by Product Catalog (2012-2017) 41
Figure Gross Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Product Catalog (2012-2017) 42
Figure 2016 Gross Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Product Catalog 42
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin by Product Catalog (2012-2017) 43
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) by Drug Type (2012-2017) 43
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Share (%) by Drug Type (2012-2017) 43
Figure Revenue Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Drug Type (2012-2017) 44
Figure 2016 Revenue Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Drug Type 45
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross (M USD) by Drug Type (2012-2017) 45
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Share (%) by Drug Type (2012-2017) 45
Figure Gross Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Drug Type (2012-2017) 46
Figure 2016 Gross Market Share (%) of Drugs for Herpes Labialis (Oral Herpes) by Drug Type 47
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin by Drug Type (2012-2017) 47
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) by Applications (2012-2017) 48
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) by Applications (2012-2017) 48
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) by Applications (2012-2017) 49
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) by Applications in 2016 49
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue Growth Rate (%) by Applications (2012-2017) 50
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Growth Rate (%) by Applications (2012-2017) 50
Table GSK Company Profile 51
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of GSK 52
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of GSK 53
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of GSK 2016-2017 53
Table Novartis Company Profile 54
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Novartis 55
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Novartis 2016-2017 55
Table Teva Company Profile 56
Table Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Teva 57
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Teva 2016-2017 59
Table Mylan Company Profile 59
Table Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Mylan 60
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Mylan 2016-2017 62
Table Cadila Company Profile 62
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Cadila 63
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Cadila 2016-2017 64
Table Apotex Company Profile 64
Table Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Apotex 65
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Apotex 2016-2017 66
Table Daewoong Company Profile 66
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Daewoong 67
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Daewoong 2016-2017 68
Table Livzon Company Profile 68
Table Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Livzon 69
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Livzon 2016-2017 70
Table Luoxin Company Profile 70
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Luoxin 72
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Luoxin 2016-2017 72
Table Med shine Company Profile 73
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Med shine 74
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Med shine 2016-2017 74
Table Bayer (Campho Phenique) Company Profile 75
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Bayer (Campho Phenique) 76
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Bayer (Campho Phenique) 2016-2017 76
Table Blistex Company Profile 77
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Blistex 78
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Blistex 2016-2017 78
Table Kelun Group Company Profile 79
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Kelun Group 80
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Kelun Group 2016-2017 80
Table Hikma Company Profile 81
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Hikma 82
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Hikma 2016-2017 82
Table Haiwang Company Profile 82
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Haiwang 83
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Haiwang 2016-2017 84
Table Carmex Company Profile 84
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Carmex 85
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Carmex 2016-2017 85
Table Cipher Company Profile 86
Figure Drugs for Herpes Labialis (Oral Herpes) Product Introductions of Cipher 87
Table Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD), Cost (M USD), Gross (M USD) and Gross Margin of Cipher 2016-2017 87
Table Key Raw Materials Suppliers 88
Table Major Raw Materials Suppliers with Contact Information of Drugs for Herpes Labialis (Oral Herpes) 89
Table Manufacturing Cost Structure of Drugs for Herpes Labialis (Oral Herpes) 91
Figure Brazil Overview of Average Monthly Wages 2015-2016 (BRL/Month) 92
Figure Argentina Overview of Average Monthly Wages 2012-2016 (ARS/Month) 93
Figure Mexico Overview of Average Monthly Wages 2012-2016(MXN/Day) 93
Figure USA Labor Cost Analysis 94
Figure Cost of Employing a Factory Worker 95
Figure 2016 Estimated Labour Costs for the Whole Economy in EuropeR 96
Figure Monthly Minimum Wages in Asia 2016 96
Figure China Labor Costs 97
Table Average Price of Electricity to Ultimate Customers 98
Figure Electricity Prices for Household Consumers in 2016 100
Figure Summary of the Driving Assumptions 101
Figure Industrial Electric Rates 2016 (PER KWH) 101
Figure Manufacturing Process Analysis of Drugs for Herpes Labialis (Oral Herpes) 103
Figure Drugs for Herpes Labialis (Oral Herpes) Industrial Chain Analysis 104
Table Major Buyers of Drugs for Herpes Labialis (Oral Herpes) 105
Figure Marketing Channels of Drugs for Herpes Labialis (Oral Herpes) 108
Table Distributors/Traders List 110
Table Market Drivers of Drugs for Herpes Labialis (Oral Herpes) 111
Figure Global GDP Growth Rate for 2015 112
Figure US GDP 2006-2016 (Billion USD) 113
Figure US CPI Change 2016-2017 113
Figure EU GDP 2006-2016 (Billion USD) 114
Figure EU CPI Change 2012-2016 114
Figure Germany GDP 2006-2016 (Billion USD) 115
Figure Germany CPI Change 2016-2017 115
Figure UK GDP 2006-2016 (Billion USD) 116
Figure UK CPI Change 2016-2017 116
Figure Italy GDP 2006-2016 (Billion USD) 117
Figure Italy CPI Change 2016-2017 117
Figure Japan GDP 2006-2016 (Billion USD) 118
Figure Japan CPI Change 2012-2016 118
Figure China GDP 2006-2016 (Billion USD) 119
Figure China CPI Change 2016-2017 119
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) and Growth Rate Forecast (2017-2022) 120
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Forecast by Regions (2017-2022) 120
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Forecast by Regions (2017-2022) 121
Figure North America Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 122
Figure Europe Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 123
Figure Rest of Asia Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 124
Figure Latin America Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 125
Figure Middle East and Africa Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 126
Figure China Drugs for Herpes Labialis (Oral Herpes) Revenue and Growth Rate (%) Forecast (2017-2022) 127
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Forecast by Product Catalog (2017-2022) 127
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) Forecast by Product Catalog (2017-2022) 128
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin Forecast by Product Catalog (2017-2022) 128
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Forecast by Drug Type (2017-2022) 128
Figure Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share (%) Forecast by Drug Type (2017-2022) 129
Table Global Drugs for Herpes Labialis (Oral Herpes) Gross Margin Forecast by Drug Type (2017-2022) 129
Table Global Drugs for Herpes Labialis (Oral Herpes) Revenue (M USD) Forecast by Application (2017-2022) 130
Figure Global Drugs for Herpes Labialis (Oral Herpes) Sales Forecast by Application (2017-2022) 130
Table Research Programs/Design for This Report 132
Figure Bottom-up and Top-down Approaches for This Report 134
Figure Data Triangulation 135
Table Key Data Information from Secondary Sources 136
Table Key Data Information from Primary Sources 137
  • United States Cefprozil Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 114
    In this report, the United States Cefprozil market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Cefpro......
  • Global Polymixin Sales Market Report 2017
    Published: 13-Nov-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the global Polymixin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Polymixin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast ......
  • Global Drugs for Toxoplasmosis Market Professional Survey Report 2017
    Published: 10-Nov-2017        Price: US 3500 Onwards        Pages: 100
    This report studies Drugs for Toxoplasmosis in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Turing Pharmaceutical - Snowdon - Guangzhou Baiyunshan Pharmaceuti......
  • Global Cefprozil Sales Market Report 2017
    Published: 10-Nov-2017        Price: US 4000 Onwards        Pages: 114
    In this report, the global Cefprozil market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Cefprozil for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast ......
  • Global Polymixin Market Professional Survey Report 2017
    Published: 09-Nov-2017        Price: US 3500 Onwards        Pages: 104
    This report studies Polymixin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Shengxue Dacheng - Apeloa - Livzon Group - LKPC - Xellia - B......
  • Global Ganciclovir Market Research Report 2017
    Published: 09-Nov-2017        Price: US 2900 Onwards        Pages: 105
    In this report, the global Ganciclovir market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ganciclovir in these regions, from 2012 to 2022 (forecast), covering - North America - Europe China Japan - ......
  • Global and Regional Cephalosporin Market Research Report 2017
    Published: 07-Nov-2017        Price: US 3500 Onwards        Pages: 180
    Summary Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections.Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium" Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - First Generation - Second Generation......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Cephalosporin Market 2017 Forecast to 2022
    Published: 06-Nov-2017        Price: US 4880 Onwards        Pages: 118
    "Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium""." Scope of the Report: This report focuses on the Cephalosporin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions,......
  • Global Tigecycline Market Research Report 2017
    Published: 03-Nov-2017        Price: US 2900 Onwards        Pages: 118
    In this report, the global Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Tigecycline in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs